ArticlebioRxiv : the preprint server for biology2025
Multimodal Fusion Analysis of [18F]Florbetapir PET and Multiscale Functional Network Connectivity in Alzheimer's Disease.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Accumulation of amyloid-beta plaques and disruption of intrinsic brain networks are two important characteristics of Alzheimer's disease (AD), yet the relationship between amyloid accumulation and network dysfunction remains unclear. In this study, we integrated [18F]Florbetapir PET and resting-state fMRI (rsfMRI) derived Functional Network Connectivity (FNC) from 552 temporally matched longitudinal PET-rsfMRI sessions across 395 participants spanning Cognitively Normal (CN), Mild Cognitive Impairment (MCI), and AD stages. With a model order of 11, joint Independent Component Analysis (jICA) was applied to the fused PET-FNC data, identifying 11 stable components, of which 9 PET-derived components corresponded to previously characterized brain regions or networks. The multimodal analysis revealed disease progression markers, including (1) a pattern of reduced subject loadings across clinical stages (CN > MCI > AD) in white matter and cerebellar regions, reflecting structural degeneration; (2) increased amyloid accumulation in affected individuals in grey matter regions, particularly in frontal, sensorimotor, extended hippocampal, and default mode network (DMN) regions, accompanied by functional connectivity alterations that reflected both compensatory and disruptive network dynamics. We identified PET-derived components that captured distinct stages of disease progression, with the DMN component emerging as a late-stage biomarker and a white matter component showing early-stage changes with limited progression thereafter. Additionally, several components showed significant variation in loadings between APOE ε4 carriers and non-carriers, linking the multimodal signatures to a well-established genetic risk factor for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.